Trial | Lead author | Year | Data type | Intervention | N | ACR20 (%) | Mean RA duration (years) |
---|---|---|---|---|---|---|---|
1 | Genovese | 2008 | IPD | Tocilizumab | 803 | 60.8 | 9.8 |
1 | Genovese | 2008 | IPD | Placebo | 413 | 24.5 | 9.8 |
2 | Smolen | 2008 | IPD | Tocilizumab | 418 | 53.1 | 7.4 |
2 | Smolen | 2008 | IPD | Placebo | 204 | 26.5 | 7.8 |
3 | Maini | 1999 | AD | Infliximab | 340 | 57.4 | 8.3 |
3 | Maini | 1999 | AD | Placebo | 88 | 22.7 | 8.9 |
4 | Weinblatt | 2003 | AD | Adalimumab | 209 | 60.3 | 12.7 |
4 | Weinblatt | 2003 | AD | Placebo | 62 | 14.5 | 11.1 |
5 | Keystone | 2004 | AD | Adalimumab | 419 | 62.1 | 11.0 |
5 | Keystone | 2004 | AD | Placebo | 200 | 29.5 | 10.9 |
6 | Chen | 2008 | AD | Adalimumab | 35 | 54.3 | 6.2 |
6 | Chen | 2008 | AD | Placebo | 12 | 33.3 | 8.3 |
7 | Kay | 2008 | AD | Golimumab | 137 | 61.3 | 7.9 |
7 | Kay | 2008 | AD | Placebo | 35 | 37.1 | 5.6 |
8 | Keystone | 2009 | AD | Golimumab | 178 | 59.6 | 5.6 |
8 | Keystone | 2009 | AD | Placebo | 133 | 27.8 | 6.5 |
9 | Kremer | 2010 | AD | Golimumab | 257 | 43.6 | 8.8 |
9 | Kremer | 2010 | AD | Placebo | 129 | 24.8 | 7.4 |
10 | Schiff | 2011 | AD | Infliximab | 165 | 59.4 | 7.3 |
10 | Schiff | 2011 | AD | Placebo | 110 | 41.8 | 8.4 |
11 | Emery | 2013 | AD | Golimumab | 318 | 61.6 | 3.5 |
11 | Emery | 2013 | AD | Placebo | 160 | 49.4 | 2.9 |
12 | Kim | 2013 | AD | Infliximab | 71 | 50.7 | 9.8 |
12 | Kim | 2013 | AD | Placebo | 72 | 30.6 | 7.4 |
13 | Tanaka | 2013 | AD | Golimumab | 173 | 72.8 | 8.4 |
13 | Tanaka | 2013 | AD | Placebo | 88 | 33.0 | 8.7 |
14 | Weinblatt | 2013 | AD | Golimumab | 395 | 58.5 | 6.9 |
14 | Weinblatt | 2013 | AD | Placebo | 197 | 24.9 | 7.0 |